Do polymer-free drug-coated stents improve safety and efficacy compared to bare metal stents in patients with high bleeding risk?
Polymer-free drug-coated stents maintain safety and efficacy benefits over bare metal stents at 2 years in high bleeding risk patients.
Safety and efficacy benefits of DCS over BMS were maintained for 2 years in high bleeding risk patients. Rates of major bleeding and coronary thrombotic events were no different and were associated with a substantial and comparable mortality risk. (A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding LEADERS FREE; NCT01623180).
Garot et al. (Sun,) studied this question.